340B Drug Pricing Program
A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and bipartisan health care challenges.
Many Americans may be unaware that the services they rely on every day through their local hospital are supported by a program called the 340B Drug Pricing Program.
Congress has passed the Consolidated Appropriations Act of 2026 (H.R.7148), which consists of a short-term continuing resolution for the Department of Homeland Security (DHS) appropriations bill and a package of five full-year appropriations bills, containing conferenced legislation for the…
- Legislation and Legislative Advocacy
- Medicaid
- Medicare
- Medicare Sequestration Payment Reductions
- Cybersecurity
- Rural issues
- Workforce
- Child and Adolescent Health
- Maternal Health
- Medical Education and Research
- Access to Behavioral Health
- Substance Use Disorder
- Disaster Preparedness
- 340B Drug Pricing Program
The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and Company policy from taking effect on Feb. 1, including by “assessing civil monetary penalties for intentionally overcharging 340B hospitals.”
AHA urges HRSA to stop Eli Lilly’s new claims-data submission policy on 340B hospitals from going into effect; hospitals urged to submit their own letters to HRSA and use AHA letter as a guide.
The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all dispensations of all Lilly drugs, regardless of setting.
The federal government has dropped its appeal of a preliminary injunction blocking implementation of the Department of Health and Human Services’ 340B Rebate Model Pilot Program.
Several health care groups, including the AHA, today told the Centers for Medicare & Medicaid Services it is wrong to tell hospitals and health systems they “are to” complete the agency’s Outpatient Prospective Payment System Drug Acquisition Cost Survey and urged CMS to correct an FAQ issued…
The First Circuit recognized that the district court’s decision halting the 340B Rebate Program was “careful and thorough”— and correct. The AHA remains pleased that these courts have put on hold this harmful program that would have a devastating effect on America’s most vulnerable patients and…
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four safety-net health systems challenging the Department of Health and Human Services’ 340B Rebate Model Pilot Program. This means that the…